Catabasis- POLARIS DMD

Phase 3 POLARIS DMD Trial

Hub Summary

POLARIS DMD is a global, placebo controlled, Phase 3 trial for edasolonexent (CAT-1004). Edasalonexent is an NF-kB inhibitor, which could provide an alterntive to steroids. Edasalonexent has been shown to preserve muscle function and substantially slow Duchenne disease progression in the MoveDMD trial.

This trial will evaluate the efficacy and safety of edasolonexent in patients with DMD, and is intended to support an application for commercial licencing of edasolonexent.

Study Number: not on

Description by Catabasis Pharmaceuticals

The POLARIS DMD study is a global Phase 3 study to evaluate the efficacy and safety of edasalonexent (CAT-1004) in boys 4 to 7 years old affected by DMD.

Two boys will receive edasalonexent for each boy that receives placebo and after 12 months, all boys are expected to receive edasalonexent in an open-label extension. Edasalonexent is an oral therapy.

Edasalonexent is a potential foundational therapy that is being developed for all patients affected by DMD. Edasalonexent inhibits NF-kB, which drives inflammation, fibrosis and muscle degeneration and suppresses muscle regeneration.


Contact the Catabasis clinical team with any questions or interest in the POLARIS DMD trial at

Primary Outcome Measures

  • Change in the North Star Ambulatory Assessment score after 12 months of treatment with edasalonexent compared to placebo

Secondary Outcome Measures

  • Timed function tests time to stand, 4-stair climb and 10-meter walk/run

  • Additional assessments of growth, cardiac and bone health

Can I take part?

Inclusion Criteria

  • Age 4 to 7 (up to 8th birthday)
  • Able to complete timed function tests

Exclusion Criteria

  • Not on corticosteroids for at least 6 months
  • Not on other investigational therapies for at least 1 month
Download PDF
Trial Status
Not yet recruiting
Trial Sponsor
Catabasis Pharmaceuticals
4-7 years
Mutation Specific
Non-mutation specific therapies
Muscle Biopsy
No Muscle Biopsy Required
Phase 3
Length Of Participation
12 months, followed by optional open-label extension
Recruitment Target
Therapeutic Category
Steroid alternative